Squire Trial

A multicenter, phase III trial in 1093 patients

Explore the results of the trial by using your login information at The Lancet®

Financial Assistance

Lilly PatientOne Co-pay Program
Lilly PatientOne
Co-pay Program:

See if your
patients qualify

Lilly PatientOne

For questions about financial
assistance for your patients specific
to Portrazza, please call
Lilly PatientOne at 1-866-472-8663

Resources and Downloads
Resources and Downloads

Take advantage of
educational resources

Self Care Kit
Self-Care Kit

Help patients manage their skin
and nails during treatment

Lilly Logo
Phone Icon

Call the Lilly Answers Center

Comment Icon

Submit a Question

Visit Lilly Icon

Visit LillyMedical.com


FDA=Food and Drug Administration; NSCLC=non-small cell lung cancer.

The Lancet® is a registered trademark of Reed Elsevier Properties S.A.

Reference: 1. Portrazza (necitumumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.